Literature for voxilaprevir (S29.001 inhibitor)

(Topics flags: I Inhibitor. To select only the references relevant to a single topic, click the link above. See explanation.)

2019
1. Pham,L.V., Jensen,S.B., Fahnoe,U., Pedersen,M.S., Tang,Q., Ghanem,L., Ramirez,S., Humes,D., Serre,S.B.N., Schonning,K., Bukh,J. and Gottwein,J.M.
   HCV genotype 1-6 NS3 residue 80 substitutions impact protease inhibitor activity and promote viral escape
   J Hepatol70, 388-397. PubMed  Europe PubMed DOI  I
2018
2. Lawitz,E., Yang,J.C., Stamm,L.M., Taylor,J.G., Cheng,G., Brainard,D.M., Miller,M.D., Mo,H. and Dvory-Sobol,H.
   Characterization of HCV resistance from a 3-day monotherapy study of voxilaprevir, a novel pangenotypic NS3/4A protease inhibitor
   Antivir Ther23, 325-334. PubMed  Europe PubMed DOI  I
2016
3. Rodriguez-Torres,M., Glass,S., Hill,J., Freilich,B., Hassman,D., Di Bisceglie,A.M., Taylor,J.G., Kirby,B.J., Dvory-Sobol,H., Yang,J.C., An,D., Stamm,L.M., Brainard,D.M., Kim,S., Krefetz,D., Smith,W., Marbury,T. and Lawitz,E.
   GS-9857 in patients with chronic hepatitis C virus genotype 1-4 infection: a randomized, double-blind, dose-ranging phase 1 study
   J Viral Hepat23, 614-622. PubMed  Europe PubMed DOI  I